Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Alexion/P&G Pexelizumab Failed Phase III Could Compromise Development Partnership

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The APEX-AMI study of pexelizumab in patients with acute myocardial infarction failed to meet its endpoint of reduction in mortality.

You may also be interested in...



Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris

The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.

Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris

The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.

Alexion Will Submit Soliris BLA By Year-End

The company will await final data from the 12-month SHEPHERD study to submit eculizumab for paroxysmal noctural hemoglobinuria.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS064417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By